HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of NRAS-Mutant Melanoma

NRAS-mutant melanoma is currently a challenge to treat. This is due to an absence of inhibitors directed against mutant NRAS, along with adaptive and acquired resistance of this tumor type to inhibitors in the MAPK pathway. Inhibitors to MEK have shown some promise for NRAS-mutant melanoma. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Parris, Joshua L.D., Barnoud, Thibaut, Leu, Julia I.-Ju, Leung, Jessica C., Ma, Weili, Kirven, Nicole A., Poli, Adi Naryana Reddy, Kossenkov, Andrew V., Liu, Qin, Salvino, Joseph M., George, Donna L., Weeraratna, Ashani T., Chen, Qing, Murphy, Maureen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849551/
https://www.ncbi.nlm.nih.gov/pubmed/35187538
http://dx.doi.org/10.1158/2767-9764.CRC-21-0033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849551/
https://www.ncbi.nlm.nih.gov/pubmed/35187538
http://dx.doi.org/10.1158/2767-9764.CRC-21-0033

Ejemplares similares